ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$233.29
+0.63%Year over year
Reported trailing growth
- Revenue
- +95.1%
- EBITDA
- +773.2%
- EBIT
- +654.9%
- EPS
- +347.0%
- Free cash flow
- +1141.6%
- Operating cash flow
- +4183.2%
Forward estimates
Based on analyst estimates
- Revenue
- +39.6%
- EBITDA
- +57.0%
- EPS
- +49.6%
Three-year CAGR
- Revenue
- +53.0%
- EBITDA
- +453.1%
- EBIT
- +383.6%
- Net income
- +212.8%
- EPS
- +209.6%
- Free cash flow
- +233.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026